Choroba Leśniowskiego-Crohna: badanie fazy III leku guselkumab
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Warszawa. Najwięcej badań dotyczy: nowotwór, choroba sercowo-naczyniowa, choroba układu pokarmowego, choroba metaboliczna.
1152 badania: 1050 rekrutuje, 102 wkrótce zaczną.
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced…
EFS of the DUO System for Tricuspid Regurgitation
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive…
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE)
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Change History and Adopt a Robotic SolutioN for anGioplasty procedurE
A Phase 2/3,PSMA-T4, Prostate Cancer
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well…
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 17 listopada 2026.